The liver is at the centre of everything we do
A clinical stage life sciences company developing
end-to-end solutions for patients with advanced liver disease
Our Story
Pioneering the next paradigm in liver disease treatment
One critical path.
Three targets.
Three potential treatments.
Pipeline
Created by doctors for patients with advanced liver disease
We are poised to deliver clinical and commercial success
Team
7th Jan 2021
Preliminary results from Carbalive and Dialive trials signal potential for new therapies to treat decompensated cirrhosis and reverse liver failure
7th Jan 2021
The ALIVER Consortium announces positive results from Phase 2 equivalent trial of the novel liver dialysis device, Dialive™
7th Jan 2021
The CARBALIVE Consortium announces positive results of a Phase 2 equivalent trial of engineered macroporous carbons as a novel treatment for cirrhosis
27th Aug 2020
Yaqrit as part of the ALIVER Consortium announces completion of first randomised controlled study of DIALIVE
25th Mar 2019
First patient is treated in first-in-human placebo controlled trial investigating safety and tolerability of Carbalive in cirrhosis patients
